FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...
WVTM Channel 13 on MSN
Walker County jail death lawsuit alleges failures in medical care and oversight
Estate of Siras Theus alleges jail medical staff and officials failed to respond appropriately to worsening medical symptoms ...
Bachelor Nation star Hannah Brown shared she is recovering after having surgery for a bicorporeal septate uterus, a rare ...
12hon MSNOpinion
Execution by firing squad is horrific. Trump is bringing it back
Trump's DOJ announced last week it is bringing the practice back to federal death row. Death penalty critics are concerned ...
Mesoblast Limited (ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced a significant achievement in its pivotal Phase 3 clinical trial. The ...
Thank you for signing up! Did you know with an ad-lite subscription to Bucks Herald, you get 70% fewer ads while viewing the ...
Super Patch CEO Jay Dhaliwal on the present and the future of transdermal vitamin and medical patches. Say goodbye to ...
U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. says a farm community in Italy for people with addiction is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results